Combination of Bifunctional Alkylating Agent and Arsenic Trioxide Synergistically Suppresses the Growth of Drug-Resistant Tumor Cells  by Lee, Pei-Chih et al.
Combination of Bifunctional
Alkylating Agent and Arsenic
Trioxide Synergistically
Suppresses the Growth of
Drug-Resistant Tumor Cells1,2
Pei-Chih Lee*,†, Rajesh Kakadiya†, Tsann-Long Su†
and Te-Chang Lee*,†
*Institute of Pharmacology, School of Medicine, National
Yang-Ming University, Taipei, Taiwan, Republic of China;
†Institute of Biomedical Sciences, Academia Sinica, Taipei,
Taiwan, Republic of China
Abstract
Drug resistance is a crucial factor in the failure of cancer chemotherapy. In this study, we explored the effect of
combining alkylating agents and arsenic trioxide (ATO) on the suppression of tumor cells with inherited or acquired
resistance to therapeutic agents. Our results showed that combining ATO and a synthetic derivative of 3a-aza-
cyclopenta[a]indenes (BO-1012), a bifunctional alkylating agent causing DNA interstrand cross-links, was more ef-
fective in killing human cancer cell lines (H460, H1299, and PC3) than combining ATO and melphalan or thiotepa.
We further demonstrated that the combination treatment of H460 cells with BO-1012 and ATO resulted in severe
G2/M arrest and apoptosis. In a xenograft mouse model, the combination treatment with BO-1012 and ATO syn-
ergistically reduced tumor volumes in nude mice inoculated with H460 cells. Similarly, the combination of BO-1012
and ATO effectively reduced the growth of cisplatin-resistant NTUB1/P human bladder carcinoma cells. Furthermore,
the repair of BO-1012–induced DNA interstrand cross-links was significantly inhibited by ATO, and consequently,
γH2AX was remarkably increased and formed nuclear foci in H460 cells treated with this drug combination. In
addition, Rad51 was activated by translocating and forming foci in nuclei on treatment with BO-1012, whereas
its activation was significantly suppressed by ATO. We further revealed that ATO might mediate through the
suppression of AKT activity to inactivate Rad51. Taken together, the present study reveals that a combination
of bifunctional alkylating agents and ATO may be a rational strategy for treating cancers with inherited or acquired
drug resistance.
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Introduction
DNA alkylating agents, commonly used as chemotherapeutic drugs
for the treatment of a variety of pediatric and adult cancers [1], exert
their cytotoxic effects by directly interacting with DNA in a way that
leads to DNA lesions. There are two types of DNA alkylating agents,
namely, monofunctional and bifunctional. Mechlorethamine, a bi-
functional nitrogen mustard alkylating agent, was the first antitumor
drug introduced into clinical practice more than 50 years ago [2].
Currently, a variety of bifunctional alkylating agents, such as the ni-
trogen mustards (e.g., melphalan [3]), nitrosoureas (e.g., carmustine
[4]), alkyl sulfonates (e.g., busulfan [5]), aziridines (e.g., thiotepa
[6]), platinum drugs (e.g., cisplatin [7]), and the natural product mi-
tomycin C (MMC) [8], are still widely used for the treatment of pa-
tients with malignant diseases. Although monofunctional alkylating
agents mainly form genotoxic monoadducts to further induce muta-
genic and carcinogenic DNA lesions, bifunctional alkylating agents
form monoadducts, intrastrand cross-links, and interstrand cross-
links (ICLs) on DNA and also form DNA-protein cross-links [9].
ICLs cause replisome dissociation and collapse and, subsequently, in-
duce DNA double-strand breaks (DSBs) [9,10]. The induction of
ICLs by bifunctional alkylating agents therefore disturbs cell cycle
progression and triggers cell death. Because the repair of ICLs is a
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laborious challenge compared with other DNA damages, the for-
mation of ICLs is the critical step in the cytotoxicity of bifunctional
alkylating agents and is recognized as a critical event in targeting
cancer therapies [9]. On the basis of MMC and bis(carbamates)-
pyrrolizidines, we previously synthesized a series of bifunctional alkyl-
ating agents, bis(hydroxymethyl) of 3a-azacyclopenta[a]indene-1-yl,
and their bis(methylcarbamate) derivatives, and showed potent anti-
cancer activity in a variety of in vitro cell models and in vivo xenograft
mouse models [11]. Among the series of 3a-aza-cyclopenta[a]indenes,
BO-1012 (Figure 1A) induced a significant level of ICLs and sup-
pressed the growth of human breast carcinoma cells transplanted in
nude mice [11].
Arsenic trioxide (ATO) is an antineoplastic chemotherapeutic
agent approved for treatment of relapsed or refractory acute promye-
locytic leukemia [12]. ATO has also been reported to reduce cell vi-
ability, induce apoptosis, and inhibit tumor growth in myeloma cells
at concentrations low enough for safe use in patients [13]. Recent
studies have further demonstrated that ATO is highly effective for
Figure 1. Enhanced cytotoxicity of BO-1012 by ATO in human cancer cell lines. (A) Chemical structure of BO-1012. (B) Cytotoxicity of
human cancer cell lines to BO-1012 and ATO. Six human cancer cell lines, H460, H1299, PC3, U87, MCF7, and OEC-M1, were treated
with various concentrations of BO-1012 or ATO for 72 hours. Cell viability was determined by the WST-1 assay. (C) Enhanced cytotoxi-
city of BO-1012, melphalan, and thiotepa by ATO cotreatment in three relatively resistant cell lines. Three relatively resistant cells, H460,
H1299, and PC3, were exposed to ATO with BO-1012, melphalan, or thiotepa for 72 hours. The cell viabilities and IC50 values of BO-1012
and other two bifunctional alkylating agents in combination with or without ATO were calculated. *P < .05, **P < .001, compared with
the IC50 values of each bifunctional alkylating agent alone. (D) Synergistic cytotoxicity of BO-1012 and ATO in H460 cells. H460 cells
were treated with BO-1012 for 1 hour, washed, and then treated with ATO for 72 hours. Left: Cell viability analysis was performed. *P <
.05, **P < .001 compared with the viability of cells treated with ATO alone. Right: The isobologram analysis of CI against affected
fraction (Fa) was obtained by constant ratio combination method as described in Materials and Methods.
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triggering apoptosis in vitro in a variety of solid tumor cells and for
inhibiting tumor growth in xenograft animal models [14]. The
promising preclinical activity of ATO against solid tumors supports
further investigation of clinical applications for ATO. However, pre-
liminary reports from phase 2 clinical trials on patients with meta-
static renal cell carcinoma [15] and metastatic melanoma [16]
suggest that ATO used as a single therapeutic agent may have limited
efficacy against solid tumors.
Alternatively, numerous reports have shown that ATO can be used
in combination with agents that induce apoptosis [17–19], reduce
glutathione [18], inhibit DNA methylation [20], or induce DNA
damage [21]. ATO also enhances radiosensitivity to human cervical
carcinoma and malignant glioma cells in vitro and in vivo by en-
hancing autophagic effects and preventing tumor invasion [21–25].
Moreover, a phase 2 trial of ATO in combination with melphalan
and ascorbic acid against myeloma showed that the addition of
ATO and ascorbic acid to high-dose melphalan is safe and well tol-
erated in patients with relapsed or refractory multiple myeloma [23].
Therefore, combined treatment using ATO and other anticancer
agents may have the potential to treat malignant tumors both effec-
tively and safely.
Our early studies and others have reported that arsenic com-
pounds synergistically enhance the cytotoxicity of UV and x-ray irra-
diation, DNA alkylating agents, and cross-linking agents [21,24–26].
Numerous studies have shown that arsenic inhibits activity of pro-
teins involved in DNA repair by various mechanisms [27,28] and in-
terferes with both base excision repair and nucleotide excision repair
[29]. ATO is likely to enhance the cytotoxicity of DNA-damaging
agents by inhibiting DNA repair [26]. Therefore, the combination
of ATO and DNA-damaging agents such as bifunctional alkylating
agents is anticipated to synergistically suppress tumor growth. Be-
cause drug resistance, both inherited and acquired, is a pervasive
problem and is a key factor contributing to the failure of clinical che-
motherapy, it is of vital importance to develop a regime against can-
cers that are resistant to chemotherapeutic agents. In this study, we
conducted preclinical experiments to demonstrate that the combina-
tion of BO-1012 and ATO provides an effective strategy against tu-
mor cells with inherited and acquired drug resistance in vitro and
suppresses their growth in xenograft mouse models.
Materials and Methods
Reagents and Chemicals
BO-1012 was synthesized in a four-step reaction as described pre-
viously [11]. ATO and other reagents were purchased from Merck
(Darmstadt, Germany), and melphalan and thiotepa were from Sigma-
Aldrich (St Louis, MO). Chemicals for cell culture were obtained from
Gibco (Grand Island, NY), and fetal bovine serum was from HyClone
(Logan, UT).
Cell Lines and Cell Culture
H460 (human lung large cell carcinoma cells), H1299 (human
non–small cell lung carcinoma p53-deficient cells), PC3 (human pros-
tate carcinoma cells), U87 (human glioma cells), and MCF7 (hu-
man breast carcinoma cells) were purchased from the American
Type Culture Collection (Rockville, MD). OEC-M1 (human gingival
squamous cell carcinoma cells) was obtained from Dr C.-L. Meng
(National Defense Medical College, Taiwan) [30]. NTUB1 (human
bladder transitional carcinoma cells) and the cisplatin-resistant subline
NTUB1/P were provided by Dr Y.-S. Pu (National Taiwan University
Hospital, Taiwan) [31,32]. All cell lines (except U87, which was grown
in minimum essential medium) were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum and antibiotics and were
incubated at 37°C in a humidified atmosphere with 5% CO2.
Measurement of Cell Viability
Cell viability was assessed using the cell proliferation reagent WST-1
(Roche Molecular Biochemicals, Penzberg, Germany), which is a tetra-
zolium salt that is cleaved by mitochondrial dehydrogenase in viable
cells. In brief, 2000 to 7000 cells were seeded in each well of 96-well
plates and were incubated at 37°C overnight before drug treatment.
After a 72-hour incubation with BO-1012 alone (∼0.1-80 μM), ATO
alone (∼1-8 μM), or BO-1012 plus ATO,WST-1 solution was added to
eachwell at a 1:10 dilution, and cells were incubated at 37°C in 5%CO2
for 4 hours. Cell viability was assessed by absorbance at 460 nm using
an automatic ELISA plate reader. The values of 50% inhibition concen-
tration (IC50) for each drug were determined from dose-effect relation-
ship at six or seven concentrations of each drug using the CompuSyn
software (version 1.0.1; CompuSyn, Inc, Paramus, NJ) by Chou and
Martin based on the median-effect principle and plot. The interactions
between ATO and BO-1012 were evaluated by the Chou-Talalay com-
bination indices (CIs) [33,34], where CI < 1 indicates synergy; CI = 1,
additivity; and CI > 1, antagonism.
Modified Single-Cell Gel Electrophoresis (Comet) and DNA
ICL Repair Assays
The formation and the repair of DNA ICLs in H460 cells were
analyzed using a modified comet assay as described previously [11].
Cell Cycle Analysis
H460 cells were treated with BO-1012 and ATO, separately or in
combination, as described above. Cell cycle analysis was performed
as described previously [35]. In brief, at the end of treatment, the
attached cells were trypsinized, fixed with ice-cold 70% ethanol,
stained with 4 μg/ml propidium iodide in PBS containing 1% Triton
X-100 and 0.1 mg/ml RNase A, and then subjected to flow cyto-
metric analysis (FACScan flow cytometer; Becton Dickinson, San Jose,
CA). The cell cycle phase distribution was analyzed using ModFit LT
2.0 software (Verity Software House, Topsham, ME).
Measurement of Histone H2AX Phosphorylation
After treatment with BO-1012, ATO, or a combination of both
agents for 24, 48, or 72 hours, cells were fixed with 70% ethanol for
16 hours, washed with PBS, and incubated with mouse anti-γH2AX
antibody (Upstate, Biotechnology, Lake Placid, NY) for 2 hours,
followed by fluorescein isothiocyanate–conjugated goat antimouse
( Jackson ImmunoResearch Laboratories, West Grove, PA) for 30 min-
utes. Cells were then stained in PBS containing 4 μg/ml propidium
iodide and 0.1 mg/ml RNase A and were analyzed with a FACScan
flow cytometer. γH2AX-labeled cells were gated according to control
histograms, and their percentage in a total of 10,000 cells was calcu-
lated for each treatment.
Immunofluorescence Staining
H460 cells were cultured onto slides and then treated with BO-
1012 and ATO, separately and in combination as described above.
To visualize γH2AX or Rad51, cells were washed with cold PBS and
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fixed with 100% ice-cold methanol for 30 minutes. Slides were
washed with PBS and incubated with anti-γH2AX for 2 hours or
anti-Rad51 antibody for 4 hours at room temperature followed by
Alexa Fluor 488 or 555−conjugated secondary antibodies (Molecular
Probes, Eugene, OR), respectively, and 4′-6-diamidino-2-phenylindole
(DAPI). After mounting with 50% glycerol, slides were subjected to
confocal image analysis (Radiance 2100 System; Bio-Rad, Hertford-
shire, England). Cells with at least four γH2AX foci in nuclei were
counted manually as positive.
Apoptosis Assays
H460 cells were exposed to BO-1012, ATO, or a combination of
both agents, and then apoptosis was detected by flow cytometry
using the annexin V–FITC Apoptosis Detection Kit (Calbiochem,
La Jolla, CA) according to the manufacturer’s instructions. In the an-
nexin V flow cytometry assay, the cells positive for annexin V stain-
ing only (bottom right quadrant) and positive for both annexin V and
DNA staining (top right quadrant) represent the early and late apop-
totic populations, respectively. The cells positive for DNA staining
only (top left quadrant) represent the necrotic population.
Xenograft Mouse Model and Therapy
Animal care was approved by and followed the guidelines of the
Academia Sinica Institutional Animal Care and Utilization Com-
mittee. Male Balb/c nude mice 6 weeks of age were obtained from
the National Laboratory Animal Center (Taipei, Taiwan). The ani-
mals were housed in a specific pathogen-free environment under con-
trolled conditions of light and humidity and were given sterilized food
and water ad libitum. They were allowed to acclimate for 48 hours
after shipment before tumor inoculation was carried out. H460 (3 ×
106 cells), NTUB1 (1 × 107 cells), or NTUB1/P (1 × 107 cells) cells in
50 μl of PBS, pH 7.4, were inoculated subcutaneously into the hind
limb of mice. When the resulting tumors reached 80 to 100 mm3 in
diameter, mice were randomly assigned to different treatment groups.
ATO (5 mg/kg body weight), BO-1012 (2.5 mg/kg), or a combina-
tion of both agents was injected intravenously five times daily. BO-
1012 solution was prepared in 20% DMSO and 15% Tween 80 in
0.9% saline, whereas ATO was dissolved in 4N NaOH, diluted in
0.9% saline and neutralized with 1N HCl before injection. To mon-
itor tumor formation, the longest and shortest diameters of the tumors
were measured using calipers. Tumor volume (mm3) was calculated ac-
cording to the following formula: tumor volume = (length × width2) /
2. Mouse body weight was also measured every 2 to 3 days and used as
an indicator of the systemic toxicity of the treatment.
Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick
End Labeling Assay
The terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL) assay was performed to quantify apoptotic cells in
xenograft tumor sections using the Dead End kit (Promega, Madison,
WI) with the assistance of an autostainer (Dako, Carpinteria, CA).
The assay was carried out according to the manufacturer’s instructions.
Immunohistochemical Staining
Immunohistochemical analysis of proliferating cell nuclear antigen
(PCNA) was conducted on established tumors from mice 1 day after
treatment. One day after the last injection with drugs (day 6), three
mice from each group were killed, and tumors were sectioned and then
stained with anti-PCNA antibody (PC-10, mouse immunoglobulin G;
DakoCytomation, Carpinteria, CA). The standard immunohistochem-
ical staining was then performed according to the manufacturer’s in-
structions of LSAB2 streptavidin-biotin complex system (Dako Corp).
Western Blot Analysis
Nuclei were isolated from H460 cells using Nuclei EZ Prep Nu-
clei Isolation Kit (Sigma). Rad51, DNA-PKcs, phospho-AKT, and
AKT were analyzed by Western blot analysis technique as described
previously [30].
Statistical Analysis
All data represent at least three independent experiments. The data
are presented as means ± SE. The statistical significance of differences
was assessed using the Student’s t-test.
Results
Human Solid Tumor Cells with Inherited Resistance Were
Sensitive to the Combination of BO-1012 and ATO
We recently reported that BO-1012 exhibits potent anticancer ac-
tivity against human lymphoblastic leukemia and various solid tumors
in vitro and against tumor xenografts in vivo [11]. In this study, we first
investigated whether ATO could sensitize human solid tumor cell lines
to BO-1012–induced cell death. Six tumor cell lines (H460, H1299,
PC3, U87, MCF7, and OEC-M1) were treated with various concen-
trations of BO-1012 (∼0.1-80 μM) or ATO (∼1-8 μM) for 72 hours.
The inhibitory effect of BO-1012 against these tumor cell lines cov-
ered a wide range, with IC50 values ranging from 5.2 μM (OEC-M1
cells) to 63.8 μM (H460 cells). OEC-M1 and MCF7 cells were highly
susceptible to BO-1012, whereas H460, H1299, and PC3 cells were
more resistant (Figure 1B). Similarly, ATO was significantly more cy-
totoxic to OEC-M1 and MCF7 cells than to H460 cells (Figure 1B).
To overcome the inherited resistance of H460, H1299, and PC3
cells to BO-1012 and ATO, the tumor cell lines were cotreated with
ATO in combination with BO-1012 for 72 hours. The cytotoxic ef-
fects of combination of ATO and two clinically chemotherapeutic
drugs, melphalan and thiotepa, were also investigated for comparison.
The IC50 values of BO-1012 were significantly reduced by cotreatment
with ATO, suggesting that the cytotoxicity of BO-1012 to these in-
herited resistance cell lines was synergistically enhanced by combin-
ing BO-1012 and ATO (Figure 1C). Synergistically cytotoxic effects
were observed only in certain combinations of ATO and melphalan
or thiotepa in H460 cells and H1299 cells and not in PC3 cells (Fig-
ure 1C). Apparently, the combination of BO-1012 and ATO was more
effective in killing cancer cells than the combination of the other two
drugs and ATO. Furthermore, cotreatment of three bifunctional al-
kylating agents with ATO showed no synergistic cytotoxic effect in sus-
ceptible cell lines such as OCE-M1 and MCF7 cells (data not shown).
Because H460 cells were the most resistant to BO-1012 and ATO,
they were used to study further the synergistic effects of these two
agents. As shown in Figure 1D, treatment of H460 cells with 0 to
40 μM BO-1012 for 1 hour did not significantly reduce the cell
growth rate; however, cell viability decreased substantially when BO-
1012–treated H460 cells were subsequently exposed to ATO (0-
8 μM) for 72 hours. The interactions between ATO and BO-1012
were evaluated by the Chou-Talalay CIs [33]. The CIs in all treat-
ments were less than 1 (Figure 1D), confirming that treatment with
BO-1012 and ATO had a synergistic cytotoxic effect.
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ATO Prolongs the Duration of Cell Cycle Perturbation
Induced by BO-1012 in H460 Cells
Because DNA-damaging agents may result in the inhibition of cell
cycle progression, we investigated the effects of BO-1012, ATO, and
a combination of both agents on cell cycle progression in H460 cells.
After the treatment of H460 cells with 10 or 20 μM BO-1012 for
1 hour and subsequent treatment with 8 μM ATO for various pe-
riods, the cell cycle distribution was analyzed using a flow cytometer.
As shown in Figure 2A, 8 μM ATO alone showed a minimal effect
on the cell cycle distribution compared with the untreated control,
whereas BO-1012 treatment significantly disturbed cell cycle pro-
gression. At the concentrations used, BO-1012 treatment resulted
in the accumulation of cells in the S phase at 24 hours and in the
G2/M phase at 48 hours, and then the cell cycle distribution reverted
to the same as seen in the control at 72 hours. When BO-1012–treated
H460 cells were posttreated with ATO, significant S and G2/M arrests
were noticeable at 48 and 72 hours, respectively. We infer that the ef-
fect of ATO is mediated by inhibiting the repair of BO-1012–induced
DNA damage, resulting in prolonged cell cycle delay.
BO-1012 Cooperates with ATO to Augment Induction of
Annexin V+ Cells
Apoptosis is usually triggered by DNA damage and cell cycle distur-
bance. Furthermore, ATO alone has been shown to induce apoptosis
[36]. We therefore examined whether BO-1012 induces apoptosis,
and whether this effect could be enhanced by posttreatment with
ATO. After treatment of H460 cells with BO-1012 for 1 hour fol-
lowed by ATO treatment for 24, 48, and 72 hours, an annexin Vapop-
tosis assay was performed, and the percentage of annexin V+ cells was
determined by flow cytometry. Figure W1 shows a representative flow
cytometry histogram of apoptosis. The annexin V+ cells in the top right
and bottom right quadrants indicate late and early apoptosis, respec-
tively. As shown in Figure 2B, the combination of BO-1012 at 10
or 20 μM with ATO at 8 μM was much more effective in inducing
annexin V+ cells than either agent alone.
BO-1012 with ATO Inhibits Tumor Growth in Mice Bearing
H460 Tumor Xenografts
The synergistic cytotoxic effect of BO-1012 with ATO in cultured
cells drew us to investigate the potential benefit of combining BO-
1012 and ATO against inherited resistance H460 cells in a xenograft
animal model. H460 cells were subcutaneously inoculated into the
hind limb of nude mice. After tumor formation, the mice were treated
daily with 2.5 mg/kg BO-1012 and/or 5 mg/kg ATO through intrave-
nous (i.v.) injection for 5 days. As shown in Figure 3A, the combined
treatment of BO-1012 and ATO significantly suppressed the growth
of H460 tumors in nude mice by ∼82% (on day 25). BO-1012 and
ATO combination treatment induced an obvious tumor growth delay,
requiring 23.3 days to achieve a tumor volume of 500 mm3, compared
with 7, 7.1, and 9.4 days in untreated control, ATO alone, and BO-
1012 alone groups, respectively (Figure 3A).
At the end of the experiments (on day 25), the tumor size and
weight were determined when the animals were killed. As shown in
Figure 3B, tumor size and weight were synergistically reduced in ani-
mals treated with a combination of BO-1012 and ATO compared
with those treated with BO-1012 or ATO alone. The mouse body
weight loss, commonly used to evaluate systemic toxicity induced by
treatment, was less than 6% in animals treated with BO-1012 alone or
BO-1012 plus ATO (Figure 3C). These results indicate that BO-1012
and its combination with ATO did not cause obvious systemic toxicity.
To further examine the anticancer effects of the combination of BO-
1012 with ATO, we performed histopathologic evaluation 24 hours
after the last treatment (i.e., day 6). Using an apoptosis marker level
determined by the TUNEL assay, apoptosis was significantly increased
in tumors treated with a combination of BO-1012 and ATO. Fur-
thermore, the cell proliferation marker PCNA was markedly sup-
pressed (Figure 3D). These results indicate that combined treatment
of BO-1012 and ATO not only induced apoptotic cell death but also
inhibited tumor cell growth substantially.
Combination of BO-1012 with ATO Overcomes
Cisplatin-Resistant Bladder Urothelial Carcinoma In Vitro
and In Vivo
In addition to the cells with inherited drug resistance such as H460,
we also studied the anticancer effects of BO-1012 in combination with
ATO against cells with acquired drug resistance. NTUB1/P cells, de-
rived from the human bladder urothelial carcinoma cell line NTUB1
[31], are 60-fold more resistant to cisplatin than the parental cells
[32]. We confirmed that the IC50 values of cisplatin in NTUB1
and NTUB1/P were 3.6 and 211.7 μM, respectively. Besides, we also
found that the IC50 values of BO-1012 alone against NTUB1 and
NTUB1/P were 24.8 and 85.4 μM; and the IC50 values of ATO alone
were 0.4 and 3.8 μM, respectively. Thus, NTUB1/P cells were 3.4-
and 9.5-fold more resistant than NTUB1 cells to BO-1012 and
ATO, respectively. Using the same treatment protocol as described
in Figure 1D, we observed that there was a synergistic effect on the
inhibition of cell growth in cultures of NTUB1/P cells (Figure 4B;
the range of CI values was 0.7-0.58) but not NTUB1 cells (Figure 4A;
the range of CI values was 1.2-1.3). To confirm the anticancer activ-
ity of this combination in an animal model, we treated nude mice
bearing NTUB1 or NTUB1/P xenografts with 2.5 mg/kg BO-1012
and/or 5 mg/kg ATO (i.v. injection five times daily). ATO alone did
not effectively suppress the growth of either NTUB1 or NTUB1/P
tumors in nude mice (Figure 4, C and D, respectively). In contrast,
NTUB1 tumors were nearly completely suppressed by BO-1012,
but only a 55% reduction in tumor volume was observed in mice
bearing NTUB1/P xenografts. Remarkably, using a combination of
BO-1012 and ATO at the same doses, more than 92% reduction of
NTUB1/P tumor volume was achieved. These results indicated that
BO-1012 alone was effective against tumor growth of drug-sensitive
NTUB1 cells, whereas the combination of BO-1012 and ATO was
required for suppressing the growth of drug-resistant NTUB1/P cells.
Repair of BO-1012–Induced DNA ICLs Is Inhibited by ATO
Whereas ATO is known to regulate DNA repair pathways, experi-
ments were conducted to understand whether ATO interferes with
repair of DNA ICLs induced by BO-1012. Using the alkaline gel
shift assay, we confirmed that BO-1012, similar to melphalan and
thiotepa, can interact with DNA to form ICLs in vitro (Figure W2).
A modified comet assay was thus adopted to investigate the formation
of ICLs in H460 cells treated with BO-1012 and ATO. As shown in
Figure 5A, ICLs increased in a dose-dependent fashion in H460 cells
treated with BO-1012, melphalan, or thiotepa for 1 hour. BO-1012
induced higher levels of ICLs than melphalan or thiotepa. ATO alone
did not cause ICLs (data not shown). However, posttreatment of BO-
1012–treated H460 cells with ATO significantly delayed the repair of
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Figure 2. Cell cycle perturbation and apoptotic cell death induced by BO-1012, ATO and in combination. H460 cells were treated with 10 or
20 μM BO-1012 for 1 hour, washed, and then treated with 8 μMATO for 24, 48 or 72 hours. (A) Cell cycle analysis. At the end of treatment,
cell cycle analysis was performed by flow cytometry as described in Materials and Methods. Representative DNA histograms of three
independent experiments with similar results are shown. Cell cycle distribution was determined as described in Materials and Methods
and shown on top of each histogram. (B) Apoptotic cell analysis. At the end of treatment, the cells were subjected to analysis of apoptosis
using annexin V staining. Percentages of annexin V+ cells were calculated. *P < .05, compared with control at each time point.
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ICLs (Figure 5B). The half-life of BO-1012–induced ICLs in H460
cells was ∼26.2 hours in the absence of ATO but was ∼82.7 hours in
the presence of ATO. These results indicate that ATO is able to inter-
fere with BO-1012–induced ICLs repair.
Because ICLs could result in DNA DSBs during DNA replication
[37], we determined the effect of combining BO-1012 with ATO on
the appearance of a DSB marker, phosphorylated histone H2AX
(γH2AX) [38]. Immunofluorescence staining was adopted to exam-
ine the formation of γH2AX foci in nuclei (Figure 5, C and D). Im-
age analysis showed that BO-1012 alone induced γH2AX nuclear
foci at 48 hours, and the number of foci then declined at 72 hours;
the percentages of cells with γH2AX foci were 36.5% and 25.9% at
48 and 72 hours, respectively, compared with 6.2% and 7.2% in un-
treated cells. Although BO-1012 treatment for 24 hours did not in-
duce formation of γH2AX foci in nuclei (5.4%), a large amount of
γH2AX was accumulated in the cytosol (Figure 5C ), which is con-
sistent with the increased number of γH2AX-positive cells detected
at 24 hours by flow cytometry (Figure W3). ATO alone resulted in
only a modest increase in γH2AX foci (26.8%). However, a large
number of γH2AX nuclear foci were manifested at 24 hours in H460
cells treated with a combination of BO-1012 and ATO. The per-
centage of cells with γH2AX foci at 24 hours was more than 80%
and declined only slightly at 72 hours (60.8%). These results indicate
that ATO posttreatment enhanced the conversion of ICLs into DSBs,
accelerated the recruitment of γH2AX in nuclei, and interfered with
the repair of BO-1012–induced ICLs. Similar findings were observed
by using flow cytometric analysis (Figure W3).
ATO Mediates through Inhibition of AKT to Interfere with
Rad51-Associated Repair Activated by BO-1012
Because homologous recombination repair (HRR) and nonhomol-
ogous end-joining are two major repair pathways of DNA DSB, we
therefore examined the nuclear translocation of Rad51 and DNA-
PKcs, components of repair machineries of HRR and nonhomolo-
gous end-joining, respectively, in H460 cells treated with BO-1012,
ATO, and in combination. As shown in Figure 6A, BO-1012 sig-
nificantly induced translocation of Rad51 and DNA-PKcs to nucleus,
whereas ATO alone did not affect the translocation of these two
proteins. However, in BO-1012–treated cells, Rad51 accumulation
in the nucleus was remarkably decreased by posttreatment with
ATO, but DNA-PKcs accumulation in nucleus was not changed.
We further confirmed the inhibitory effects of ATO on Rad51 ac-
tivation by immunohistochemical technique (Figure 6B). Our re-
sults showed that BO-1012 resulted in substantially increased Rad51
foci in nuclei. Consistent to Western blot analysis, ATO alone did
Figure 3. Synergistic anticancer activity of ATO and BO-1012 combination on the H460 xenograft. The nude mice with H460 xenograft
were injected daily i.v. with 5 mg/kg ATO, 2.5 mg/kg BO-1012, or a combination of both agents for 5 days. (A) Tumor volumes. The
numbers of animal in each group are six to seven. The tumor volumes were measured with calipers every 2 or 3 days, and these are
expressed as mean ± SE. (B) Representative images of the mice bearing the tumors one the 25th day. The average tumor weights are
shown at the bottom. *P < .05 compared with control. (C) Body weight change of mice. The body weights were measured every 2 or
3 days. (D) PCNA immunohistochemistry and TUNEL assay. Xenograft tumor sections from each group at 1 day after the last treatment
(i.e., the sixth day after the first treatment) were taken out, sectioned, and subjected for PCNA immunohistochemistry and TUNEL assay
as described in Materials and Methods.
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not induce Rad51 foci in nucleus, but it did significantly reduce
Rad51 foci in the nuclei of BO-1012–treated cells. These results in-
dicated that BO-1012–induced damage could activate Rad51 and/or
DNA-PKcs–associated repair machineries; however, ATO could in-
hibit Rad51 activation and, subsequently, enhance the anticancer effect
of BO-1012.
Previous studies reported that the phosphoinositide 3-kinase (PI3K)–
AKT signaling pathway modulates the expression or activation of
Rad51 [39,40]. We therefore determined AKT activity in H460 cells
treated with BO-1012, ATO, and in combination. As shown in Fig-
ure 6C , AKTwas activated by BO-1012 by accumulation of pAKT,
whereas combined treatment of BO-1012 and ATO significantly in-
hibited BO-1012–elicited AKT activity. To confirm the involvement
of activated PI3K-AKT in BO-1012–triggered Rad51 activation,
BO-1012–treated H460 cells were exposed to PI3K-AKT inhibitors,
wortmannin, or AKTi. Our results showed that inhibition of AKT
accompanied with decreased translocation of Rad51 into nuclei in
BO-1012–treated cells (Figure 6D). These results suggest that ATO
may mediate through the inhibition of AKT activity to interfere with
Rad51 activation triggered by BO-1012.
Discussion
Either inherited or acquired resistance to chemotherapeutic drugs is a
major limitation of therapy for cancer patients. A high capacity for
DNA repair in cancer cells is frequently noted as one resistance mech-
anism [41]. In recent decades, novel therapeutic strategies and drug
designs have been of great interest in cancer chemotherapy. The pres-
ent study is the first to report a potent and a rational strategy for cancer
Figure 4. Synergistic anticancer activity of ATO and BO-1012 combination on human bladder cancer cells, NTUB1, and derived cisplatin-
resistant NTUB1/P cells. (A and B) Cell viability analysis of BO-1012, ATO, and the combination of NTUB1 (A) and NTUB1/P (B) cells. Cell
viability was assayed as described in Figure 1B. *P < .05 compared with ATO alone at each concentration. Bottom: The isobologram
analysis of CI against affected fraction (Fa) was obtained by the constant-ratio combination method as described in Materials and Meth-
ods. (C and D) The anticancer activity of BO-1012, ATO, and in combination against NTUB1 (C) and NTUB1/P (D) tumors. The mice
bearing NTUB1 or NTUB1/P xenografts were treated with individual drugs or in combination as described in Figure 3A. The numbers
of animal in each group are four to six. The tumor volumes were measured with calipers at the indicated time points, and these are
expressed as mean ± SE.
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therapy using a combination of BO-1012, a newly synthesized MMC
derivative [11], with ATO, an agent that inhibits DNA repair. This
drug combination strategy effectively suppressed the growth of H460
human large cell lung carcinoma in culture and in a xenograft mouse
model compared with treatment with either agent alone. H460 cells
were relatively resistant to several chemotherapeutic treatments, such
as BO-1012, ATO, melphalan, and thiotepa (Figure 1), compared with
other human solid tumors. Moreover, the therapeutic efficacy in mice
bearing H460 xenografts is not convincing using conventional chemo-
therapy alone or in combination with ionizing radiation; although
H460 tumor growth is inhibited during the drug-treated period,
growth rapidly resumes after treatment [42,43]. H460 cells therefore
provide an inherited resistant line for assessing efficacy of new treat-
ments. In this study, we found that a combination of ATO and BO-
1012 provided enhanced inhibition of tumor growth of H460 cells
compared with BO-1012 alone.
In addition, we evaluated the effectiveness of this drug combina-
tion in cells with acquired cisplatin resistance. Platinum chemothera-
pies have become the most commonly prescribed chemotherapeutic
drugs for treating solid cancers in patients [44]. Platinum resistance is
a major clinical problem because there are no known drugs that can
be used to circumvent this tumor resistance. We found that treatment
with BO-1012 in combination with ATO was more effective in inhib-
iting the growth of an acquired cisplatin-resistant human bladder
cancer, NTUB1/P, than was treatment with either single agent. Be-
cause the growth rate of NTUB1/P cells in nude mice was apparently
faster than the parental NTUB1 cells, whether the growth rate playing
certain roles on the synergism of BO-1012 and ATO remained to
Figure 5. Inhibition of the repair of BO-1012 induced DNA damage and exaggeration of DSB formation by ATO. (A) Induction of ICLs by BO-
1012, melphalan, and thiotepa. H460 cells were treated with various concentrations of BO-1012, melphalan, or thiotepa for 1 hour and then
subjected for a modified comet assay as described in Materials and Methods. Percentage of DNA ICLs was calculated by the percentage
of decrease in tail moment. (B) Inhibition of the repair of BO-1012–induced DNA ICLs by ATO. H460 cells were treated with 40 μMBO-1012
for 1 hour, washed, and then treated with 8 μMATO for 16, 24, and 48 hours. *P< .05 compared with BO-1012 alone at the indicated time
point. (C) Enhanced formation of BO-1012–induced γH2AX nuclei foci by ATO. H460 cells were treated with BO-1012, ATO, or in combi-
nation as described previously. After treatment, the detection of γH2AX (green) immunofluorescence staining was performed as described
in Materials and Methods. Nuclei were counterstained with DAPI (blue). (D) The percentages of the cells containing four or more γH2AX
nuclei foci were determined under a fluorescent microscope. *P < .05 compared with control at each time point.
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be clarified. Nevertheless, our study revealed that the combination of
BO-1012 and ATO might be an effective regime for treatment of hu-
man cancer cells with inherited or acquired drug resistance.
A large number of synthetic and natural bifunctional alkylating
agents exhibit anticancer activity because they can induce DNA ICLs
[8,45]. The natural anticancer agent MMC and its analog(s) have
been reported to cross-link to DNA double strands [46], and several
synthetic bifunctional alkylating agents are under development [11].
The recently synthesized BO-1012 has been demonstrated to be a
potent anticancer agent in vitro and in xenograft mouse models
[11]. The mechanism of this agent’s anticancer activity is thought
to lie in the induction of DNA ICLs and further cellular responses.
Once a replication fork stall or collapse is induced by treatment with
bifunctional alkylating agents, repair pathways are required to recog-
nize the problem and permit the resumption of replication. When
collapsed replication forks are recognized, they trigger cell cycle ar-
rest, DNA repair, or cell death through apoptosis [47]. In the present
study, we confirmed that BO-1012 exerts its anticancer effect by in-
ducing DNA ICLs, which may lead to DSBs, cell cycle arrest, and,
finally, cell death. Compared with clinically used alkylating agents,
melphalan and thiotepa, BO-1012 apparently induces a higher level
of ICLs (Figures 5A and W3), and its combination with ATO exhib-
its potent anticancer activity.
Our present results demonstrate that DNA lesions induced by
BO-1012 are still reparable, especially in relatively resistant cancer
cells such as H460 cells. The efficacy of anticancer drugs is highly
dependent on DNA repair capacity. Numerous studies have shown
that cells defective in DNA repair exhibit sensitivity to cancer ther-
apeutic agents such as etoposide, MMC, and ionizing radiation [48].
Unfortunately, a high degree of DNA repair activity is frequently ob-
served in malignant cells, which results in resistance to chemothera-
peutic drugs [48,49]. Inhibition of DNA repair activity is therefore a
valuable strategy to enhance the efficacy of anticancer chemothera-
peutics. A previous study has reported that resistance to O6-alkylating
agents can be overcome by depletion of a DNA repair protein, O6-
methylguanine-DNA methyltransferase [50]. In fact, DNA repair
proteins are targets for anticancer drug development [51]. The com-
bination of the DNA damaging agent temozolomide with inhibitors
of O6-methylguanine-DNA methyltransferase is currently under clin-
ical trials [52]. Arsenic has been reported to impair base excision re-
pair activity by down-regulation of DNA polymerase β (Pol β) and
AP endonuclease [53] and to inhibit PARP-1 [54] and XPA [55] ac-
tivity through competitive interaction with zinc. Our biochemical
and immunological studies demonstrated that ATO could inhibit
the activation of Rad51 in cells exposed to BO-1012.
Rad51 has been well documented to play a representative role on
HRR-mediated DSB repair and cellular resistance to chemotherapies
[56]. Functionally, when DNA DSB is formed by DNA-damaging
agents, Rad51 interacted with chromatin and formed oligomers [56].
Several reports have shown that AKT may play important roles on
modulation of Rad51-associated HRR [39,40]. In the present study,
we demonstrated that AKT and Rad51 activations triggered by BO-
1012 treatment were suppressed by ATO. These results suggest that
ATO may mediate through the inhibition of AKT to interfere with
DNA repair pathway, particularly Rad51-associated repair.
Emerging evidence has shown that ATO is an effective therapeutic
for treatment of patients with relapse/refractory acute promyelocytic
leukemia and multiple myeloma, with only mild adverse effects re-
ported [12,57]. ATO-based chemotherapy is therefore a promising
Figure 6. Inhibition of BO-1012–triggered Rad51 activation by ATO
through decreased AKT activity. H460 cells were treated with 40 μM
BO-1012 for 1 hour, washed, and then treated with 8 μM ATO for
24 hours. (A) Western blot analysis of Rad51 and DNA-PKcs in nu-
clear extracts (NE) and whole-cell extracts (WCE). At the end of
treatment, an aliquot of NE and WCE were separated on a 10%
SDS–polyacrylamide gel. Rad51 and DNA-PKcs were visualized
by immunoblot analysis technique as described in Materials and
Methods. Oct-1 and β-actin were included on the blot as loading
controls for NE and WCE, respectively. (B) Immunofluorescence
staining of Rad51. At the end of treatment, the cells were fixed
and stained with primary antibody against Rad51 and then Alexa
Fluor 555–conjugated secondary antibody (red) as described in
Materials and Methods. Nuclei were counterstained with DAPI
(blue). (C) Western blot analysis of AKT and pAKT. AKT and pAKT
in WCE were analyzed as described in panel A using antibodies
against AKT and p-AKT, respectively. (D) Inhibition of BO-1012 in-
duced Rad51 translocation by wortmannin and AKTi. H460 cells
were treated with 40 μM BO-1012 for 1 hour and followed with
wortmannin (1 μM) or AKTi (20 μM) for 24 hours. After treatments,
the nuclear extracts were subjected to Western blot analysis for
Rad51 as described in Materials and Methods.
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treatment option for patients who tolerate or fail to respond to treat-
ment with other chemotherapy regimens [57]. Because the high
doses of ATO used for treatment of solid tumors are associated with
clinical risks [58], the combination of ATO with other therapeutic
agents may be a good strategy to reduce the ATO dose. In the present
study, ATO at subtoxic doses was able to cooperate with BO-1012 to
effectively suppress human solid tumor growth.
In the present study, we found that cell lines, such as H460,
H1299, PC3, and NTUB1/P cells, that are more resistant to BO-
1012 responded well to the addition of ATO, the combined treat-
ment with BO-1012 and ATO and, therefore, may reveal a new clue
for improving therapeutic efficacy of cancers with inherited or ac-
quired drug resistance.
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Figure W1. Apoptotic cell death induced by BO-1012, ATO, and in combination. H460 cells were treated with 20 μM BO-1012 for 1 hour,
washed, and then treated with 8 μM ATO for 24, 48, or 72 hours. After treatment, the cells were subjected to analysis of apoptosis using
annexin V staining. Representative flow cytometry analysis of apoptotic cell death.
Figure W2. Formation of DNA ICLs by BO-1012, melphalan, and
thiotepa. pEGFP-N1 plasmid DNA was incubated with various con-
centrations of drugs. At the end of treatment, the DNA ICLs were
analyzed by alkaline gel shift assay as described in Materials and
Methods. ss indicates single-strand DNA; cross-links, DNA ICLs.
Figure W3. Enhancement of histone H2AX phosphorylation by
BO-1012, ATO, and in combination. H460 cells were treated with
20 μM BO-1012 for 1 hour, washed, and then treated with 8 μM
ATO for 24, 48, or 72 hours. (A) Flow cytometric analysis of
γH2AX. After treatment, flow cytometry analysis of γH2AX was
performed as described in Materials and Methods. (B) Percentage
of γH2AX-positive cells. The γH2AX-positive cells in the rectangle
of each dot plot (A) were gated.
